API | vadastuximab talirine

vadastuximab talirine Report issue

Biologics mAb ADC Experimental

AACT DrugBank PubChem

Active Ingredient History

NOW

Vadastuximab talirine is an antibody-drug conjugate (ADC) directed to CD33 (siglec-3) which is a transmembrane receptor expressed on cells of myeloid lineage. The experimental drug, being developed by Seattle Genetics, was in clinical trials for the treatment of acute myeloid leukemia (AML). ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
vadastuximab talirine

More Chemistry

Pharmacology

Mechanism of Action:
- Myeloid cell surface antigen CD33 (Homo sapiens) ^UniProt
Multi-specific: No
Payload: pyrrolobenzodiazepine
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

sgn-cd33a | vadastuximab talirine

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Leukemia, Myeloid, Acute (Phase 3)

Leukemia, Promyelocytic, Acute (Phase 1)

Myelodysplastic Syndromes (Phase 1/Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue